140 related articles for article (PubMed ID: 31667787)
1. CCND1 silencing suppresses liver cancer stem cell differentiation through inhibiting autophagy.
Zhang H
Hum Cell; 2020 Jan; 33(1):140-147. PubMed ID: 31667787
[TBL] [Abstract][Full Text] [Related]
2. CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma.
Ding H; Wang Y; Zhang H
J Pharmacol Sci; 2020 Jul; 143(3):219-225. PubMed ID: 32418739
[TBL] [Abstract][Full Text] [Related]
3. Degradative autophagy selectively regulates CCND1 (cyclin D1) and MIR224, two oncogenic factors involved in hepatocellular carcinoma tumorigenesis.
Wu SY; Lan SH; Liu HS
Autophagy; 2019 Apr; 15(4):729-730. PubMed ID: 30646811
[TBL] [Abstract][Full Text] [Related]
4. [A study of gene amplification and expression of cyclin D1 in hepatocellular carcinoma].
Xu JM; Wen JM; Zhang M; Lü GL; Wu LZ; Wang WS
Zhonghua Bing Li Xue Za Zhi; 2004 Feb; 33(1):26-30. PubMed ID: 14989924
[TBL] [Abstract][Full Text] [Related]
5. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment.
Song YJ; Zhang SS; Guo XL; Sun K; Han ZP; Li R; Zhao QD; Deng WJ; Xie XQ; Zhang JW; Wu MC; Wei LX
Cancer Lett; 2013 Oct; 339(1):70-81. PubMed ID: 23879969
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA PTTG3P functions as an oncogene by sponging miR-383 and up-regulating CCND1 and PARP2 in hepatocellular carcinoma.
Zhou Q; Zhang W; Wang Z; Liu S
BMC Cancer; 2019 Jul; 19(1):731. PubMed ID: 31340767
[TBL] [Abstract][Full Text] [Related]
7. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
Li J; Chen JN; Zeng TT; He F; Chen SP; Ma S; Bi J; Zhu XF; Guan XY
BMC Cancer; 2016 Jan; 16():15. PubMed ID: 26758620
[TBL] [Abstract][Full Text] [Related]
8. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α.
Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK
Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451
[TBL] [Abstract][Full Text] [Related]
9. Oxytetracycline have the therapeutic efficiency in CD133
Song Y; Kim IK; Choi I; Kim SH; Seo HR
Sci Rep; 2018 Oct; 8(1):16100. PubMed ID: 30382122
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in cyclin D1 gene and hepatocellular carcinoma.
Zhang YJ; Chen SY; Chen CJ; Santella RM
Mol Carcinog; 2002 Feb; 33(2):125-9. PubMed ID: 11813305
[TBL] [Abstract][Full Text] [Related]
11. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
12. Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133
Song Y; Park IS; Kim J; Seo HR
Chem Biol Interact; 2019 Aug; 309():108713. PubMed ID: 31226288
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis.
Ma YS; Lv ZW; Yu F; Chang ZY; Cong XL; Zhong XM; Lu GX; Zhu J; Fu D
J Exp Clin Cancer Res; 2018 Oct; 37(1):252. PubMed ID: 30326936
[TBL] [Abstract][Full Text] [Related]
14. TPX2 silencing exerts anti‑tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway.
Huang DH; Jian J; Li S; Zhang Y; Liu LZ
Int J Mol Med; 2019 Dec; 44(6):2113-2122. PubMed ID: 31638175
[TBL] [Abstract][Full Text] [Related]
15. Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression via autophagy and the CD133 feedback loop.
Wang X; Deng Q; Feng K; Chen S; Jiang J; Xia F; Ma K; Bie P
Oncol Rep; 2018 Jul; 40(1):241-251. PubMed ID: 29749472
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.
Liu YM; Li XF; Liu H; Wu XL
Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320
[TBL] [Abstract][Full Text] [Related]
17. 8-bromo-5-hydroxy-7-methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling.
Ren KQ; Cao XZ; Liu ZH; Guo H; Quan MF; Liu F; Jiang L; Xiang HL; Deng XY; Cao JG
Int J Oncol; 2013 Nov; 43(5):1719-29. PubMed ID: 23970349
[TBL] [Abstract][Full Text] [Related]
18. Luteolin Promotes Cell Apoptosis by Inducing Autophagy in Hepatocellular Carcinoma.
Cao Z; Zhang H; Cai X; Fang W; Chai D; Wen Y; Chen H; Chu F; Zhang Y
Cell Physiol Biochem; 2017; 43(5):1803-1812. PubMed ID: 29049999
[TBL] [Abstract][Full Text] [Related]
19. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
[TBL] [Abstract][Full Text] [Related]
20. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
